Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Kathleen R Whiteman, MS, Paul Noordhuis, PhD, Russell Walker, MS, Krystal Watkins, MS, Yelena Kovtun, PhD, Lauren Harvey, BS, Alan Wilhelm, BS, Holly Johnson, BS, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 2321.

https://doi.org/10.1182/blood.V124.21.2321.2321

Published: 2014

Journal Articles

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

Jutta Deckert, PhD, Jose F. Ponte, PhD, Jennifer A. Coccia, Leanne Lanieri, Sharon Chicklas, Yong Yi, Krystal Watkins, Rodrigo Ruiz-Soto, MD MSc, Angela Romanelli, PhD, Robert J. Lutz, PhD

Blood (2014) 124 (21): 3119.

https://doi.org/10.1182/blood.V124.21.3119.3119

Published: 2014

Journal Articles

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Leonard T Heffner, MD, Sundar Jagannath, MD, Todd M Zimmerman, MD, Kelvin P Lee, MD, Jacalyn Rosenblatt, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Niklas Czeloth, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4042.

https://doi.org/10.1182/blood.V120.21.4042.4042

Published: 2012

Journal Articles

Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,

Jutta Deckert, Ph.D., Sharon Chicklas, Yong Yi, Min Li, Jan Pinkas, Ph. D., Thomas Chittenden, Ph.D., Robert J. Lutz, PhD, Peter U. Park, Ph.D.

Blood (2011) 118 (21): 3726.

https://doi.org/10.1182/blood.V118.21.3726.3726

Published: 2011

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher Chanan-Khan, MD, Leonard T. Heffner, MD, David Avigan, MD, Todd M. Zimmerman, MD, Sagar Lonial, MD, Robert J. Lutz, PhD, Andre Engling, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Michelle A. Beelitz, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2011) 118 (21): 305.

https://doi.org/10.1182/blood.V118.21.305.305

Published: 2011

Journal Articles

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

Chantal Zuber, PhD, Benjamin Daelken, PhD, Silke Aigner, PhD, Thomas Haeder, PhD, Olga Ab, PhD, Kathleen Whiteman, PhD, Teru Hideshima, Robert J Lutz, PhD, Frank Osterroth, PhD, Christoph Uherek, PhD

Blood (2010) 116 (21): 3008.

https://doi.org/10.1182/blood.V116.21.3008.3008

Published: 2010

Journal Articles

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, MD, Asher A. Chanan-Khan, MD, Leonard T Heffner, MD, David Avigan, MD, Robert J Lutz, PhD, Christoph Uherek, PhD, Frank Osterroth, PhD, Markus Ruehle, MD, Thomas Haeder, PhD, Gabriele Niemann, PhD, Andrea Wartenberg-Demand, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson

Blood (2010) 116 (21): 3060.

https://doi.org/10.1182/blood.V116.21.3060.3060

Published: 2010

Journal Articles

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Leonard T. Heffner, David Avigan, MD, Kelvin P. Lee, MD, Robert J Lutz, PhD, Thomas Haeder, PhD, Markus Ruehle, MD, Christoph Uherek, PhD, Andrea Barbara Wartenberg-Demand, MD, Nikhil Munshi, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 1862.

https://doi.org/10.1182/blood.V114.22.1862.1862

Published: 2009

NARROW

The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations

Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)

BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity

Potent B-Cell Depletion by IMGN529, a CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies,

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy In Combination with Lenalidomide or Bortezomib

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Phase I Study of BT062 Given as Repeated Single Dose Once Every 3 Weeks in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only